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objectives: The aim was to determine the cost-effectiveness of colonic stent inser-
tion for the management of malignant bowel obstructions. Colonic stents are a 
minimally invasive alternative to open surgery for patients medically unfit for single 
stage surgery. MethoDs: Two economic models were developed. The first compared 
patients who received palliative or definitive stents and were not medically fit for 
re-anastomosis. The second compared patients who received stents as a bridge-to-
surgery and were medically fit for a second stage of two-stage surgery, this included 
colostomy or Hartmann’s procedure. ResultsFor patients requiring palliation, the 
cost of colonic stent insertion was estimated to be $17,809 compared to $20,516 for 
palliative colostomy (a saving of $2,707). The benefits associated with both proce-
dures were 0.099 QALYs and 0.089 QALYs gained, respectively, an incremental benefit 
of 0.01 QALYs per patient. For patients requiring a bridge-to-surgery, the cost of 
colonic stent insertion was estimated to be $29,729, compared to $30,169 for patients 
that received multi-stage surgery (either a colostomy or a Hartmann’s procedure). 
This represented a cost savings of $440. The estimated average patient would gain 
0.510 QALYs compared to 0.458 QALYs in the multi-stage surgery group. This yields 
an incremental benefit of 0.052 QALYs per patient. The main drivers of both models 
were the technical and clinical success of the stent insertion, and length of hospital 
stay following the procedures. The probability of a resection with primary anas-
tomosis after insertion of a stent and the cost of stenting were also drivers in the 
bridge-to-surgery model. conclusions: In terms of cost-effectiveness, colonic 
stent insertion for malignant bowel obstruction in patients requiring palliation or 
a bridge-to-surgery dominated the current alternative surgical procedures.
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objectives: The aim of this study is to develop and validate a decision-analytic 
model describing the current course of disease, including treatment, in metastatic 
colorectal cancer. This baseline model will serve as the comparator in analyses of the 
(cost-) effectiveness of new treatment strategies. MethoDs: An individual-based 
micro-simulation model was constructed based on the disease states a patient 
may experience after a diagnosis of metastatic colorectal cancer. The states include 
first-line second-line and third-line treatment, as well as states of progression of 
disease after first-, second- or third-line, finally a death state is included. Time spent 
in each disease state was predicted using log-logistic, log-normal or weibull survival 
models, each dependent on a number of patient characteristics. All survival models 
and patient characteristics were based on patient-level data, provided by the CAIRO 
trial (NCT00312000). Two oncologists evaluated the model for face validity, the model 
was further validated by comparing various model outcomes with the original data, 
the national cancer registry and a population based study. results: There were no 
significant differences in patient and treatment characteristics, nor intermediate 
and overall survival estimates between the simulated and original patient-level 
data. External validation with national cancer registry data showed few differences 
in survival with the simulated data. Additionally the simulated survival did not 
significantly differ from the survival as recorded in a pilot oxaliplatin study of 119 
patients who were observed in the same timeframe as the RCT. conclusions: The 
micro-simulation decision model described in this article underwent an internal 
and external validation and can be used to evaluate new possibilities for research 
and treatment in metastatic colorectal cancer.
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objectives: The evaluation of the economic consequences of 21-gene RT-PCR assay 
OncotypeDX introduction to the reimbursement scheme of National Organization 
for Health Provision-EOPYY. MethoDs: A decision tree was developed concerning 
two treatment scenarios for the year 2013: a) chemotherapy admission according the 
common treatment practice without the application of the test vs b) chemotherapy 
admission depending on the results of the test. The sub-group of breast cancer 
patients appropriate for applying the test was determined according international 
guidelines and included early stage breast cancer women with hormone receptor 
positive and lumph node negative age ≤ 65 years. Cancer incidence was derived from 
ELSTAT and OECD base, while some assumptions were made concerning the age 
structure and disease stage of the population. The percentages of women assessed 
as high risk (score> 31) for recurrence were obtained from EOPYY data for 2013. The 
estimated cost for OncotypeDX test was set according the EOPYY reimbursement 
price (€ 2,848 for 2013). Cost of chemotherapy and other cost items (eg laboratory 
sectable osteosarcoma using national guideline recommendations. MethoDs: 
An economic disease model was developed based on recommendations from the 
2013 NCCN Clinical Practice Guidelines in Oncology for bone cancer. The model 
quantified resource use for diagnosis, 12 months of treatment, and 12 months 
of surveillance of a metastatic unresectable osteosarcoma patient. Costs in 2014 
dollar value were derived from publically available sources for reimbursement of 
CPT codes, HCPCS codes, and generic WAC prices for medications. Chemotherapy 
dosing was based on NCCN recommended treatment regimens. results: The 
diagnostic cost was estimated to be $1,706 per patient. Treatment costs, consist-
ing of stereotactic radiosurgery and chemotherapy with drug monitoring, varied 
widely across the four NCCN recommended regimens due to differences in the 
price of pharmacotherapy. The chemotherapy regimens were estimated to be the 
major cost components associated with this disease. Doxorubicin, cisplatin, and 
high-dose methotrexate cost $103,051 per patient; doxorubicin and cisplatin cost 
$17,549 per patient; doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide 
cost $38,404 per patient; and cisplatin, ifosfamide, and epirubicin cost $38,936 per 
patient. Additionally, stereotactic radiosurgery was estimated at $2,755 per patient, 
and the cost of drug monitoring during the one year of chemotherapy averaged to 
$5,899 per patient. Additionally, one year of disease surveillance cost $4,264 per 
patient. conclusions: A guideline-based disease model can assist health plans 
to better understand and anticipate the expected diagnosis, treatment, and sur-
veillance resources and costs for unresectable metastatic osteosarcoma patients.
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objectives: The objective of this cost study was to measure the resource utilisa-
tion and the direct costs associated with health care management of metastatic 
malignant melanoma (mMM) in Slovakia and provide a basis for cost-effectiveness 
evaluations. MethoDs: The cross-sectional survey was performed and included 3 
oncologists experienced in mMM management. The survey was performed to obtain 
the information on the management of patients with mMM and to estimate the 
direct costs of the disease. The studied population were 3 cohorts of mMM patients 
which are usually identified as the health states in the cost-effectiveness models: 
“Before progression“, “Disease progression“ and “Terminal care“. Costs of drugs 
were assesed separately from health states and rated particularly according to BRAF 
positivity. The cost data were assessed for the year 2013. All types of health care used 
in mMM management were evaluated (outpatient and inpatient visits, diagnostics, 
prescription drugs and medical examinations). Costs of adverse events (AEs) were 
set for one single event. results: The most frequent treatment regimens used in 
the first treatment line of BRAF mutant and BRAF negative patients were identical 
- dacarbazin (94.9% of treated patients), fotemustin (4.5%) and ipilimumab (0.6%). 
Monthly costs of mMM management in addition to the active treatment in the 
state “Before progression“ count for 6.64% (€ 188.51/patient), during the “Disease 
progression“ it was 45.56% (€ 1 294.31/patient) and during the “Terminal state of 
patient“ 47.80% (€ 1 358.02/patient). Adverse event (AE) costs were evaluated for 
grade 3 and 4. The most costly AEs were neutropenia (€ 1 014.66), fever (€ 364.87) and 
rash (€ 230.35). conclusions: In the management of mMM (excluding the active 
drug cost), the most expensive are the costs of hospitalization and symptomatic 
treatment. The most costly period is the “Terminal state“.
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objectives: The EHR4CR 4-year research partnership between the European Union 
and the European Federation of Pharmaceutical Industries and Associations (EFPIA) 
has developed a platform for the trustworthy reuse of hospital electronic health 
records’ data for clinical research. A cost-benefit assessment (CBA) was conducted 
from the pharmaceutical industry perspective to assess the value of the first two 
EHR4CR clinical research scenarios (S): Protocol feasibility assessment (S1), and 
Patient identification and recruitment (S2), either used individually or sequentially 
within a clinical trial workflow, versus current practices. MethoDs: The EFPIA 
partners have conducted a resource utilization assessment to calculate the actual 
person-time and cost of performing S1 and S2 for one oncology clinical study (Phase 
II or Phase III) as reference case. Assuming that an estimated 50% reduction in actual 
person-time and cost under EHR4CR conditions would directly translate in acceler-
ated time to market (TTM), potential benefits to global pharmaceutical industry were 
derived using global market values (2012) of oncology products1. Absolute cost-ben-
efit analyses were conducted using Monte-Carlo simulations. results: Compared 
to current practices, individual EHR4CR scenarios S1 and S2 have yielded efficiency 
gains of 134 days and 37 days respectively, and of 171 days when used sequentially. 
Should these efficiency gains from study design optimisation translate in faster 
TTM, corresponding estimated benefits for the global pharmaceutical oncology 
franchise could reach 160,45, and 205 Million € , respectively. conclusions: This 
CBA is the first to assess the value of EHR4CR scenarios for oncology clinical trials. 
The results confirm that the EHR4CR platform could generate substantial added 
value for pharmaceutical industry should its efficiency gains translate in faster 
TTM. Further benefits are expected from the EHR4CR platform in other therapeutic 
